Therapeutic drug for traumatic neural disease (disorder) and/or motor function disorder

Abstract

The object is to provide a therapeutic drug for traumatic neural disease (disorder) and/or motor function disorder, more particularly, a therapeutic drug for traumatic neural disease (disorder) and/or motor function disorder derived from spinal cord injury. A keratan sulfate oligosaccharide or a derivative thereof was found to have an effect of improving the traumatic neural disease (disorder) and/or motor function disorder derived from spinal cord injury and to be useful as the therapeutic drug for traumatic neural disease (disorder) and/or motor function disorder. That is, according to the present invention, there is provided a therapeutic drug for traumatic neural disease (disorder) and/or motor function disorder comprising an effective amount of the keratan sulfate oligosaccharide or the derivative thereof.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph showing an effect of L4 on hind limb motor function in a rat spinal cord injury model according to a crush method with forceps, where a relation between the hind limb motor function (BBB score) and days after treatment of spinal cord injury and administration of L4 is shown;

FIG. 2 is a graph showing the effect of L4 on the hind limb motor function in the rat spinal cord injury model according to the crush method with forceps, where the hind limb motor function (BBB score) on the seventh day after the treatment of spinal cord injury and the administration of L4 is shown; and

FIG. 3 is a graph showing an effect of L4 on spinal cord evoked potential in the rat spinal cord injury model according to the crush method with forceps, where the spinal cord evoked potential on the seventh day after the treatment of spinal cord injury and the administration of L4 is shown.

Claims

1. A therapeutic drug for traumatic neural disease (disorder) comprising an effective amount of a keratan sulfate oligosaccharide or a derivative thereof.

2. A therapeutic drug for motor function disorder comprising an effective amount of a keratan sulfate oligosaccharide or a derivative thereof.

3. The therapeutic drug according to claim 2, wherein the motor function disorder is derived from neuropathy.

4. The therapeutic drug according to claim 1, wherein the neuropathy is derived from spinal cord injury.

5. The therapeutic drug according to any one of claim 1, wherein the keratan sulfate oligosaccharide is one of disaccharides represented by the following formulae or an oligosaccharide of even-numbered sugars containing one or both of disaccharides represented by the following formulae as repeating structural units: Gal(6S)-GlcNAc(6S) andGal(6S)-GlcNAcwherein Gal represents a galactose residue; GlcNAc represents an N-acetylglucosamine residue; 6S means that a hydroxyl group at position 6 is in the form of 6-O-sulfate ester; and—represents a glycosidic bond.

6. The therapeutic drug according to claim 5, wherein the keratan sulfate oligosaccharide is any one of oligosaccharides represented by the following formulae: Gal(6S)β1-4GlcNAc(6S)β1-3Gal(6S)β1-4GlcNAc(6S)Gal(6S)β1-4GlcNAc(6S) andGal(6S)β1-4GlcNAcwherein Gal represents a galactose residue; GlcNAc represents an N-acetylglucosamine residue; 6S means that a hydroxyl group at position 6 is in the form of 6-O-sulfate ester; β1-4 represents a β-1,4-glycosidic bond; and β1-3 represents a β-1,3-glycosidic bond.

7. The therapeutic drug according to claim 1, wherein the derivative of the keratan sulfate oligosaccharide is an acylated derivative thereof at a hydroxyl group(s).

8. The therapeutic drug according to claim 7, wherein the derivative of the keratan sulfate oligosaccharide is represented by the following formula:

9. The therapeutic drug according to claim 8, wherein all of X1 to X5 are acyl groups having 1 to 10 carbon atoms and M is an alkali metal.

10. The therapeutic drug according to claim 9, wherein the derivative of the keratan sulfate oligosaccharide is represented by the following formula: